Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

147P - Blind validation of an AI-based tool for predicting distant relapse from breast cancer HES stained slides

Date

10 Sep 2022

Session

Poster session 01

Topics

Pathology/Molecular Biology;  Translational Research;  Digital Health and Real World Data (eHealh, Telehealth, Big Data);  Molecular Oncology

Tumour Site

Breast Cancer

Presenters

Ingrid Garberis

Citation

Annals of Oncology (2022) 33 (suppl_7): S55-S84. 10.1016/annonc/annonc1038

Authors

I.J. Garberis1, V. Gaury2, V. Aubert3, D. Drubay4, C. Saillard2, K. Elgui5, F. bernigole6, A. Jacquet7, F. André8, M. Lacroix-Triki9

Author affiliations

  • 1 Ile De France, Institut Gustave Roussy - INSERM UMR 981, 94405 - Villejuif/FR
  • 2 75, OWKIN France, 75010 - Paris/FR
  • 3 Biostat, OWKIN France, 75010 - Paris/FR
  • 4 Biostatistics, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 5 Paris, OWKIN France, 75010 - Paris/FR
  • 6 Pathology, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 7 Réseau And Development, Unicancer, 75654 - Paris/FR
  • 8 Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 9 Biology And Pathology Department, Institut Gustave Roussy, 94805 - Villejuif/FR
More

Abstract 147P

Background

Correctly classifying early invasive breast cancer (eiBC) cases into high-risk and low-risk is considered a key issue in breast cancer treatment. This classification is notably crucial in determining the treatment regimen: chemo-endocrine therapy versus, endocrine therapy alone. Last year, we presented RACE, an AI-based tool for assessing the risk of distant relapse at 5 years of ER+HER2- eiBC patients from HES (hematoxylin-eosin-safran) whole slide images (WSI). In the present study, we performed a one-shot blind validation of RACE on an independent cohort of 676 HES WSI.

Methods

HES WSI of 676 ER+/HER2- eiBC diagnosed at Gustave Roussy from 2012 to 2017 included in the CANTO cohort, constituted the validation dataset (19 patients relapsed at 5 years). We compared RACE performance to the two most relevant clinical scores: Predict Breast and CTS0. To assess performance, we proceeded as follows. The scores were first compared in terms of both cumulative sensitivity and dynamic specificity at 5 years to assess the accuracy of the scores to identify relapses. For this purpose, each score has been binarized (low risk/high risk) with respect to a threshold that has been set beforehand.

Results

The cumulative sensitivity (resp. dynamic specificity) at 5 years is 64% (resp. 78%) for Race, 61% (resp. 77%) for CTS0 and 43% (resp. 80%) for Predict Breast. Further analyses showed that among the low risk population treated with endocrine therapy alone, the distant relapse rate was 0.3% (1 out of 324).

Conclusions

We performed a first fully blind validation of Race, an AI-based tool for assessing the risk of distant relapse. First, the obtained results showed the ability of RACE to generalize on independent data and thus endorse the soundness of the method. Furthermore, additional analysis brings to light the clinical value of Race and that it could be used for therapeutic de-escalation purposes. This validation will be extended to multi-site and multi-scanner eiBC WSI from the CANTO cohort under completion.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy.

Funding

Owkin.

Disclosure

V. Gaury, V. Aubert, C. Saillard, K. Elgui: Financial Interests, Personal, Stocks/Shares: Owkin. F. André: Financial Interests, Personal, Advisory Role: Owkin. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.